CoChat
Sign Up
Cited by 89Cholesterol and Lipid MetabolismAlzheimer's disease research and treatmentsBarrier Structure and Function Studies

Lipoproteins in the Central Nervous System: From Biology to Pathobiology

Open access
Raulin, Ana-Caroline, Martens, Yuka A., Bu, Guojun·2022·Annual Review of Biochemistry
DOI 10.1146/annurev-biochem-032620-104801PMC PMC9634960
Open this paper in CoChat — free account

Abstract

The brain, as one of the most lipid-rich organs, heavily relies on lipid transport and distribution to maintain homeostasis and neuronal function. Lipid transport mediated by lipoprotein particles, which are complex structures composed of apolipoproteins and lipids, has been thoroughly characterized in the periphery. Although lipoproteins in the central nervous system (CNS) were reported over half a century ago, the identification of APOE4 as the strongest genetic risk factor for Alzheimer's disease has accelerated investigation of the biology and pathobiology of lipoproteins in the CNS. This review provides an overview of the different components of lipoprotein particles, in particular apolipoproteins, and their involvements in both physiological functions and pathological mechanisms in the CNS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1146/annurev-biochem-032620-104801

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 193 · Cited by 89

Research works printed but not linked: 145

  1. [1]Sastry PS. 1985. Lipids of nervous tissue: composition and metabolism. Prog. Lipid Res 24: 69– 176 3916238
  2. [2]Mahley RW. 2016. Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism. Arterioscler. Thromb. Vase. Biol 36: 1305– 15 PMC4942259 27174096
  3. [4]Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg HJ, 2001. Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res 42: 1143– 51 11441143
  4. [5]Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, 1993. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. PNAS 90: 1977– 81 8446617 PMC46003
  5. [6]Beisiegel U, Spector AA. 2001. Lipids and lipoproteins in the brain. Curr. Opin. Lipidol 12: 243– 44 11353325
  6. [7]Elliott DA, Weickert CS, Garner B. 2010. Apolipoproteins in the brain: implications for neurological and psychiatric disorders. Clin. Lipidol 51: 555– 73 21423873 PMC3058497
  7. [8]Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. 1987. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem 262: 14352– 60 3115992
  8. [9]Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, 2001. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294: 1354– 57 11701931
  9. [10]Hayashi H, Campenot RB, Vance DE, Vance JE. 2007. Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J. Neurosci. 27: 1933– 41 17314289 PMC6673537
  10. [12]Jurevics H, Morell P. 1995. Cholesterol for synthesis of myelin is made locally, not imported into brain. J. Neurochem 64: 895– 901 7830084
  11. [13]Dietschy JM, Turley SD. 2001. Cholesterol metabolism in the brain. Curr. Opin. Lipidol 12: 105– 12 11264981
  12. [14]Steck TL, Lange Y. 2010. Cell cholesterol homeostasis: mediation by active cholesterol. Trends Cell Biol. 20: 680– 87 20843692 PMC2967630
  13. [15]Roca-Agujetas V, Barbero-Camps E, de Dios C, Podlesniy P, Abadin X, 2021. Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease. Mol. Neurodegener 16: 15 33685483 PMC7941983
  14. [18]Bahrami A, Barreto GE, Lombardi G, Pirro M, Sahebkar A. 2019. Emerging roles for high-density lipoproteins in neurodegenerative disorders. BioFactors 45: 725– 39 31301192
  15. [19]Mahley RW, Innerarity TL, Rail SC Jr., Weisgraber KH. 1984. Plasma lipoproteins: apolipoprotein structure and function. J. Lipid Res 25: 1277– 94 6099394
  16. [20]Havel RJ, Yamada N, Shames DM. 1987. Role of apolipoprotein E in lipoprotein metabolism. Am. Heart J 113: 470– 74 3544762
  17. [21]Mahley RW. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622– 30 3283935
  18. [22]Weisgraber KH, Mahley RW. 1980. Subfractionation of human high density lipoproteins by heparin-sepharose affinity chromatography. J. Lipid Res 21: 316– 25 7381326
  19. [23]Bu G 2009. Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci 10: 333– 44 19339974 PMC2908393
  20. [24]Zhao N, Liu C-C, Qiao W, Bu G. 2018. Apolipoprotein E, receptors, and modulation of Alzheimer’s disease. Biol. Psychiatry 83: 347– 57 28434655 PMC5599322
  21. [25]Zhang J, Liu Q. 2015. Cholesterol metabolism and homeostasis in the brain. Protein Cell 6: 254– 64 25682154 PMC4383754
  22. [27]Quan G, Xie C, Dietschy JM, Turley SD. 2003. Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Brain Res. Dev. Brain Res 146: 87– 98 14643015
  23. [28]Nieweg K, Schaller H, Pfrieger FW. 2009. Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J. Neurochem 109: 125– 34 19166509
  24. [29]Lanfranco MF, Ng CA, Rebeck GW. 2020. ApoE lipidation as a therapeutic target in Alzheimer’s disease. Int. J. Mol. Sci 21: 6336 PMC7503657 32882843
  25. [30]Swahn B, Brönnestam R, Dencker SJ. 1961. On the origin of the lipoproteins in the cerebrospinal fluid. Neurology 11: 437– 40 13721829
  26. [31]Roheim PS, Carey M, Forte T, Vega GL. 1979. Apolipoproteins in human cerebrospinal fluid. PNAS 76: 4646– 49 291993 PMC411636
  27. [32]Koch M, Furtado JD, Falk K, Leypoldt F, Mukamal KJ, Jensen MK. 2017. Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma. Alzheimer’s Dementia 6: 182– 87 PMC5338868 28289700
  28. [33]Elshourbagy NA, Liao WS, Mahley RW, Taylor JM. 1985. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. PNAS 82: 203– 7 3918303 PMC397000
  29. [35]Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. 1985. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Investig 76: 1501– 13 3932467 PMC424114
  30. [37]Pasinetti GM, Johnson SA, Oda T, Rozovsky I, Finch CE. 1994. Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J. Comp. Neurol 339: 387– 400 8132868
  31. [39]Kim WS, Guillemin GJ, Glaros EN, Lim CK, Garner B. 2006. Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells. Neuroreport 17: 891– 96 16738483
  32. [40]Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, 2004. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem 279: 40987– 93 15269217
  33. [41]Lee J, Bu G. 2005. Genetics and molecular biology: ABCA1 in brain apolipoprotein E metabolism and lipidation. Curr. Opin. Lipidol 16: 115– 17 15650570
  34. [42]Hayden MR, Clee SM, Brooks-Wilson A, Genest J Jr., Attie A, Kastelein JJ. 2000. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr. Opin. Lipidol 11: 117– 22 10787172
  35. [43]Wellington CL, Walker EK, Suarez A, Kwok A, Bissada N, 2002. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab. Investig 82: 273– 83 11896206
  36. [44]Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, 2003. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid β secretion. J. Biol. Chem 278: 13244– 56 12547833
  37. [45]Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, 2004. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem 279: 41197– 207 15269218
  38. [46]Kim WS, Rahmanto AS, Kamili A, Rye K-A, Guillemin GJ, 2007. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-β peptide generation. J. Biol. Chem 282: 2851– 61 17121837
  39. [47]Kaminski WE, Orso E, Diederich W, Klucken J, Drobnik W, Schmitz G. 2000. Identification of a novel human sterol-sensitive ATP-binding cassette transporter (ABCA7). Biochem. Biophys. Res. Commun 273: 532– 38 10873640
  40. [48]Wang N, Lan D, Gerbod-Giannone M, Linsel-Nitschke P, Jehle AW, 2003. ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux. J. Biol. Chem 278: 42906– 12 12917409
  41. [49]Sakae N, Liu CC, Shinohara M, Frisch-Daiello J, Ma L, 2016. ABCA7 deficiency accelerates amyloid-β generation and Alzheimer’s neuronal pathology. J. Neurosci 36: 3848– 59 27030769 PMC4812140
  42. [51]Tarr PT, Edwards PA. 2008. ABCG1 and ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. J. Lipid Res 49: 169– 82 17916878
  43. [52]Wang N, Yvan-Charvet L, Lutjohann D, Mulder M, Vanmierlo T, 2008. ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain. FASEB J. 22: 1073– 82 18039927
  44. [53]Hirsch-Reinshagen V, Donkin J, Stukas S, Chan J, Wilkinson A, 2009. LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins. J. Lipid Res 50: 885– 93 19065001 PMC2666175
  45. [54]Yamada T, Kawata M, Arai H, Fukasawa M, Inoue K, Sato T. 1995. Astroglial localization of cholesteryl ester transfer protein in normal and Alzheimer’s disease brain tissues. Acta Neuropathol. 90: 633– 36 8615085
  46. [55]Rapp A, Gmeiner B, Huttinger M. 2006. Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 88: 473– 83 16376010
  47. [56]Kanekiyo T, Liu CC, Shinohara M, Li J, Bu G. 2012. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer’s amyloid-β. J. Neurosci 32: 16458– 65 23152628 PMC3508699
  48. [58]van Kerkhof P, Lee J, McCormick L, Tetrault E, Lu W, 2005. Sorting nexin 17 facilitates LRP recycling in the early endosome. EMBO J. 24: 2851– 61 16052210 PMC1187941
  49. [59]Fu Y, Zhao J, Atagi Y, Nielsen HM, Liu C-C, 2016. Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan. Mol. Neurodegener 11: 37 27151330 PMC4857252
  50. [60]Bento-Abreu A, Velasco A, Polo-Hernandez E, Perez-Reyes PL, Tabernero A, Medina JM. 2008. Megalin is a receptor for albumin in astrocytes and is required for the synthesis of the neurotrophic factor oleic acid. J. Neurochem 106: 1149– 59 18466341
  51. [61]Chun JT, Wang L, Pasinetti GM, Finch CE, Zlokovic BV. 1999. Glycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus. Exp. Neurol 157: 194– 201 10222122
  52. [62]Kounnas MZ, Loukinova EB, Stefansson S, Harmony JA, Brewer BH, 1995. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J. Biol. Chem 270: 13070– 75 7768901
  53. [63]LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, Jay G. 1997. Neuronal cell death in Alzheimer’s disease correlates with apoE uptake and intracellular Abeta stabilization. J. Clin. Investig 100: 310– 20 9218507 PMC508193
  54. [64]Wicher G, Larsson M, Fex Svenningsen A, Gyllencreutz E, Rask L, Aldskogius H. 2006. Low density lipoprotein receptor-related protein-2/megalin is expressed in oligodendrocytes in the mouse spinal cord white matter. J. Neurosci. Res 83: 864– 73 16463279
  55. [65]Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. 2016. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91: 328– 40 27477018
  56. [67]Sovic A, Balazs Z, Hrzenjak A, Reicher H, Panzenboeck U, 2004. Scavenger receptor class B, type I mediates uptake of lipoprotein-associated phosphatidylcholine by primary porcine cerebrovascular endothelial cells. Neurosci. Lett 368: 11– 14 15342124
  57. [68]Havel RJ, Kane JP. 1973. Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins. PNAS 70: 2015– 19 4352966 PMC433655
  58. [69]Shore VG, Shore B. 1973. Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components. Biochemistry 12: 502– 7 4345806
  59. [70]Utermann G, Jaeschke M, Menzel J. 1975. Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. FEBS Lett. 56: 352– 55 169165
  60. [72]Das HK, McPherson J, Bruns GA, Karathanasis SK, Breslow JL. 1985. Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J. Biol. Chem 260: 6240– 47 3922972
  61. [73]McLean JW, Elshourbagy NA, Chang DJ, Mahley RW, Taylor JM. 1984. Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing of a new variant. J. Biol. Chem 259: 6498– 504 6327682
  62. [75]Weisgraber KH, Rail SC Jr., Mahley RW. 1981. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J. Biol. Chem 256: 9077– 83 7263700
  63. [78]Medway CW, Abdul-Hay S, Mims T, Ma L, Bisceglio G, 2014. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer’s disease. Mol. Neurodegener 9: 11 24607147 PMC3995879
  64. [80]Abou Ziki MD, Strulovici-Barel Y, Hackett NR, Rodriguez-Flores JL, Mezey JG, 2014. Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations. Am. J. Cardiol 113: 302– 8 24239320 PMC3943837
  65. [81]Orth M, Weng W, Funke H, Steinmetz A, Assmann G, 1999. Effects of a frequent apolipoprotein E isoform, ApoE4Freiburg (Leu28→Pro), on lipoproteins and the prevalence of coronary artery disease in whites. Arterioscler. Thromb. Vasc. Biol 19: 1306– 15 10323784
  66. [82]Raulin AC, Kraft L, Al-Hilaly YK, Xue WF, McGeehan JE, 2019. The molecular basis for apolipoprotein E4 as the major risk factor for late-onset Alzheimer’s disease. J. Mol. Biol 431: 2248– 65 31051176 PMC6556554
  67. [83]Yokoyama S, Kawai Y, Tajima S, Yamamoto A. 1985. Behavior of human apolipoprotein E in aqueous solutions and at interfaces. J. Biol. Chem 260: 16375– 82 4066713
  68. [85]Chen J, Li Q, Wang J. 2011. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. PNAS 108: 14813– 18 21873229 PMC3169138
  69. [86]Wetterau JR, Aggerbeck LP, Rall SC Jr., Weisgraber KH. 1988. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J. Biol. Chem 263: 6240– 48 3360781
  70. [88]Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, Huang Y. 2006. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci 26: 4985– 94 16687490 PMC6674234
  71. [89]Huynh TV, Wang C, Tran AC, Tabor GT, Mahan TE, 2019. Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model. Mol. Neurodegener 14: 37 31623648 PMC6796484
  72. [90]Bruinsma IB, Wilhelmus MM, Kox M, Veerhuis R, de Waal RM, Verbeek MM. 2010. Apolipoprotein E protects cultured pericytes and astrocytes from D-Aβ1–40-mediated cell death. Brain Res. 1315: 169– 80 20034483
  73. [92]Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. 2015. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann. Neurol 77: 301– 11 25469919
  74. [95]Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, 2013. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol. Neurodegener 8: 13 23601557 PMC3640999
  75. [96]Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, 2012. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer’s disease. Hum. Mol. Genet 21: 4558– 71 22821396 PMC3459471
  76. [97]Martinez-Morillo E, Nielsen HM, Batruch I, Drabovich AP, Begcevic I, 2014. Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein E isoforms. J. Proteome Res 13: 1077– 87 24392642
  77. [102]Yamauchi K, Tozuka M, Hidaka H, Hidaka E, Kondo Y, Katsuyama T. 1999. Characterization of apolipoprotein E-containing lipoproteins in cerebrospinal fluid: effect of phenotype on the distribution of apolipoprotein E. Clin. Chem 45: 1431– 38 10471645
  78. [103]Li Z, Shue F, Zhao N, Shinohara M, Bu G. 2020. APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease. Mol. Neurodegener 15: 63 33148290 PMC7640652
  79. [105]Zhao J, Davis MD, Martens YA, Shinohara M, Graff-Radford NR, 2017. APOE ε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum. Mol. Genet 26: 2690– 700 28444230 PMC5886091
  80. [106]Garai K, Baban B, Frieden C. 2011. Dissociation of apolipoprotein E oligomers to monomer is required for high-affinity binding to phospholipid vesicles. Biochemistry 50: 2550– 58 21322570 PMC3088999
  81. [107]Hubin E, Verghese PB, van Nuland N, Broersen K. 2019. Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation. FEBS Lett. 593: 1144– 53 31058310 PMC6617784
  82. [108]Frieden C, Wang H, Ho CMW. 2017. A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions. PNAS 114: 6292– 97 28559318 PMC5474821
  83. [109]Jain RS, Quarfordt SH. 1979. The carbohydrate content of apolipoprotein E from human very low density lipoproteins. Life Sci. 25: 1315– 23 92742
  84. [110]Wernette-Hammond ME, Lauer SJ, Corsini A, Walker D, Taylor JM, Rail SC Jr. 1989. Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194. J. Biol. Chem 264: 9094– 101 2498325
  85. [111]Flowers SA, Grant OC, Woods RJ, Rebeck GW. 2020. O-glycosylation on cerebrospinal fluid and plasma apolipoprotein E differs in the lipid-binding domain. Glycobiology 30: 74– 85 31616924 PMC7335482
  86. [112]Lee Y, Kockx M, Raftery MJ, Jessup W, Griffith R, Kritharides L. 2010. Glycosylation and sialylation of macrophage-derived human apolipoprotein E analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of glycosylation on Ser290. Mol. Cell Proteom 9: 1968– 81 PMC2938105 20511397
  87. [113]Kawasaki K, Ogiwara N, Sugano M, Okumura N, Yamauchi K. 2009. Sialic acid moiety of apolipoprotein E and its impact on the formation of lipoprotein particles in human cerebrospinal fluid. Clin. Chim. Acta 402: 61– 66 19138682
  88. [114]Lalazar A, Weisgraber KH, Rall SC Jr., Giladi H, Innerarity TL, 1988. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J. Biol. Chem 263: 3542– 45 2831187
  89. [115]Weisgraber KH, Innerarity TL, Mahley RW. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem 257: 2518– 21 6277903
  90. [116]Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. 1990. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem 265: 10771– 79 2355022
  91. [118]Mann WA, Meyer N, Weber W, Meyer S, Greten H, Beisiegel U. 1995. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J. Lipid Res 36: 517– 25 7775863
  92. [119]Atagi Y, Liu C-C, Painter MM, Chen X-F, Verbeeck C, 2015. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J. Biol. Chem 290: 26043– 50 26374899 PMC4646257
  93. [120]Michikawa M, Fan QW, Isobe I, Yanagisawa K. 2000. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J. Neurochem 74: 1008– 16 10693931
  94. [124]Nathan BP, Jiang Y, Wong GK, Shen F, Brewer GJ, Struble RG. 2002. Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res. 928: 96– 105 11844476
  95. [125]Holtzman DM, Pitas RE, Kilbridge J, Nathan B, Mahley RW, 1995. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. PNAS 92: 9480– 84 7568158 PMC40825
  96. [127]Wang C, Wilson WA, Moore SD, Mace BE, Maeda N, 2005. Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol. Dis 18: 390– 98 15686968
  97. [129]Vitek MP, Brown CM, Colton CA. 2009. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 30: 1350– 60 18155324 PMC2782461
  98. [131]Maezawa I, Nivison M, Montine KS, Maeda N, Montine TJ. 2006. Neurotoxicity from innate immune response is greatest with targeted replacement of ε4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB J. 20: 797– 99 16481366
  99. [132]Blaschuk O, Burdzy K, Fritz IB. 1983. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J. Biol. Chem 258: 7714– 20 6863260
  100. [133]Jones SE, Jomary C. 2002. Clusterin. Int. J. Biochem. Cell Biol 34: 427– 31 11906815
  101. [134]Jenne DE, Tschopp J. 1992. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem. Sci 17: 154– 59 1585460
  102. [135]Wong P, Pineault J, Lakins J, Taillefer D, Leger J, 1993. Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J. Biol. Chem 268: 5021– 31 7680346
  103. [136]Burkey BF, deSilva HV, Harmony JA. 1991. Intracellular processing of apolipoprotein J precursor to the mature heterodimer. J. Lipid Res 32: 1039– 48 1658176
  104. [137]de Silva HV, Stuart WD, Park YB, Mao SJ, Gil CM, 1990. Purification and characterization of apolipoprotein J. J. Biol. Chem 265: 14292– 97 2387851
  105. [138]de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J. 1990. Apolipoprotein J: structure and tissue distribution. Biochemistry 29: 5380– 89 1974459
  106. [139]Calero M, Tokuda T, Rostagno A, Kumar A, Zlokovic B, 1999. Functional and structural properties of lipid-associated apolipoprotein J (clusterin). Biochem. J 344(Part 2): 375– 83 10567218 PMC1220653
  107. [140]Itakura E, Chiba M, Murata T, Matsuura A. 2020. Heparan sulfate is a clearance receptor for aberrant extracellular proteins. J. Cell Biol 219: jcb.201911126 PMC7054991 32211892
  108. [141]de Silva HV, Stuart WD, Duvic CR, Wetterau JR, Ray MJ, 1990. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J. Biol. Chem 265: 13240– 47 2376594
  109. [142]Borghini I, Barja F, Pometta D, James RW. 1995. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim. Biophys. Acta Lipids Lipid Metab 1255: 192– 200 7696334
  110. [143]Herring SK, Moon H-J, Rawal P, Chhibber A, Zhao L. 2019. Brain clusterin protein isoforms and mitochondrial localization. eLife 8: e48255 31738162 PMC6860991
  111. [144]Jenne DE, Lowin B, Peitsch MC, Bottcher A, Schmitz G, Tschopp J. 1991. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J. Biol. Chem 266: 11030– 36 1904058
  112. [145]Rull A, Martinez-Bujidos M, Perez-Cuellar M, Perez A, Ordonez-Llanos J, Sanchez-Quesada JL. 2015. Increased concentration of clusterin/apolipoprotein J (apoJ) in hyperlipemic serum is paradoxically associated with decreased apoJ content in lipoproteins. Atherosclerosis 241: 463– 70 26081122
  113. [146]Bonaterra-Pastra A, Fernandez-de-Retana S, Rivas-Urbina A, Puig N, Benitez S, 2021. Comparison of plasma lipoprotein composition and function in cerebral amyloid angiopathy and Alzheimer’s disease. Biomedicines 9: 72 33445800 PMC7828227
  114. [147]Suzuki T, Tozuka M, Kazuyoshi Y, Sugano M, Nakabayashi T, 2002. Predominant apolipoprotein J exists as lipid-poor mixtures in cerebrospinal fluid. Ann. Clin. Lab. Sci 32: 369– 76 12458888
  115. [150]Murphy BF, Kirszbaum L, Walker ID, d'Apice AJ. 1988. SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J. Clin. Investig 81: 1858– 64 2454950 PMC442636
  116. [151]Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. 1999. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem 274: 6875– 81 10066740
  117. [152]Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, 2011. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res. 71: 5838– 49 21737488
  118. [154]Tsujita M, Vaisman B, Chengyu L, Vickers KC, Okuhira KI, 2021. Apolipoprotein A-I in mouse cerebrospinal fluid derives from the liver and intestine via plasma high-density lipoproteins assembled by ABCA1 and LCAT. FEBS Lett. 595: 773– 88 33020907 PMC7987658
  119. [155]Stukas S, Robert J, Lee M, Kulic I, Carr M, 2014. Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus. J. Am. Heart Assoc 3: e001156 25392541 PMC4338702
  120. [156]Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. 2020. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol. Neurodegener 15: 40 32677986 PMC7364557
  121. [159]Novikova G, Andrews SJ, Renton AE, Marcora E. 2021. Beyond association: successes and challenges in linking non-coding genetic variation to functional consequences that modulate Alzheimer’s disease risk. Mol. Neurodegener 16: 27 33882988 PMC8061035
  122. [160]Seto M, Weiner RL, Dumitrescu L, Hohman TJ. 2021. Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions. Mol. Neurodegener 16: 29 33926499 PMC8086309
  123. [162]Liu C-C, Kanekiyo T, Xu H, Bu G. 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol 9: 106– 18 23296339 PMC3726719
  124. [164]Aikawa T, Holm ML, Kanekiyo T. 2018. ABCA7 and pathogenic pathways of Alzheimer’s disease. Brain Sci. 8: 27 PMC5836046 29401741
  125. [165]Beecham GW, Vardarajan B, Blue E, Bush W, Jaworski J, 2018. Rare genetic variation implicated in non-Hispanic white families with Alzheimer disease. Neurol Genet. 4: e286 30569016 PMC6278241
  126. [166]Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, 1995. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer’s disease. Neuroscience 69: 757– 61 8596645
  127. [167]Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J. 1996. Biochemical characterization of Alzheimer’s soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem. Biophys. Res. Commun 223: 592– 97 8687441
  128. [168]Permanne B, Perez C, Soto C, Frangione B, Wisniewski T. 1997. Detection of apolipoprotein E/dimeric soluble amyloid β complexes in Alzheimer’s disease brain supernatants. Biochem. Biophys. Res. Commun 240: 715– 20 9398632
  129. [169]Aleshkov S, Abraham CR, Zannis VI. 1997. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide β (1–40). Relevance to Alzheimer’s disease. Biochemistry 36: 10571– 80 9265639
  130. [170]Choi-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, 1992. SP-40,40 is a constituent of Alzheimer’s amyloid. Acta Neuropathol. 83: 260– 64 1373021
  131. [171]Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. 1991. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541: 163– 66 2029618
  132. [173]DeMattos RB, O'Dell MA, Parsadanian M, Taylor JW, Harmony JAK, 2002. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer’s disease. PNAS 99: 10843– 48 12145324 PMC125060
  133. [175]Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, 2007. Transport pathways for clearance of human Alzheimer’s amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab 27: 909– 18 17077814 PMC2853021
  134. [176]Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, 1993. The cerebrospinal-fluid soluble form of Alzheimer’s amyloid β is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J 293(Part 1): 27– 30 8328966 PMC1134315
  135. [177]Chen F, Swartzlander DB, Ghosh A, Fryer JD, Wang B, Zheng H. 2021. Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology. Mol. Neurodegener 16: 5 33517893 PMC7849119
  136. [178]Wojtas AM, Sens JP, Kang SS, Baker KE, Berry TJ, 2020. Astrocyte-derived clusterin suppresses amyloid formation in vivo. Mol. Neurodegener 15: 71 33246484 PMC7694353
  137. [181]Najm R, Jones EA, Huang Y. 2019. Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease. Mol. Neurodegener 14: 24 31186040 PMC6558779
  138. [182]Zhao J, Fu Y, Yamazaki Y, Ren Y, Davis MD, 2020. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer’s disease patient iPSC-derived cerebral organoids. Nat Commun. 11: 5540 33139712 PMC7608683
  139. [187]Williams T, Borchelt DR, Chakrabarty P. 2020. Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease. Mol. Neurodegener 15: 8 32005122 PMC6995170
  140. [188]Zhao J, Fu Y, Liu C-C, Shinohara M, Nielsen HM, 2014. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J. Biol. Chem 289: 11282– 92 24599963 PMC4036266
  141. [189]Tai LM, Koster KP, Luo J, Lee SH, Wang YT, 2014. Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J. Biol. Chem 289: 30538– 55 25217640 PMC4215234
  142. [190]Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, 2007. The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer’s disease. Mol. Cell Neurosci 34: 621– 28 17336088
  143. [191]Fan J, Zhao RQ, Parro C, Zhao W, Chou HY, 2018. Small molecule inducers of ABCA1 and apoE that act through indirect activation of the LXR pathway. J. Lipid Res 59: 830– 42 29563219 PMC5928439
  144. [192]Serrano-Pozo A, Das S, Hyman BT. 2021. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 20: 68– 80 33340485 PMC8096522
  145. [193]Rajan KB, Barnes LL, Wilson RS, McAninch EA, Weuve J, 2017. Racial differences in the association between apolipoprotein E risk alleles and overall and total cardiovascular mortality over 18 years. J. Am. Geriatr. Soc 65: 2425– 30 28898389 PMC6201232

Authors
Raulin, A.-C., Martens, Y. A., & Bu, G.
Affiliations
Mayo Clinic (US)
ORCID
Venue
Annual Review of Biochemistry
Publisher
Annual Reviews
Published
2022-06-21
Volume
91
Issue
1
Pages
731-759
ISSN
  • 0066-4154 (ISSN-L)
  • 1545-4509
DOI
10.1146/annurev-biochem-032620-104801
PMC
PMC9634960
OpenAlex
W4220978836
Cited by
89
References
193
Citations by year
2026: 29 · 2025: 26 · 2024: 20 · 2023: 9 · 2022: 5
FWCI
3.56
Type
journal article
Language
en
Open access
Locations
  • Annual Review of Biochemistry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
Funders
National Institute on Aging (R01AG066395, R37AG027924, RF1AG057181, RF1AG046205, U19AG069701)
Topics
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
lipoproteins, central nervous system, apolipoproteins, lipid transport, APOE ε4, Alzheimer's disease, lipoprotein metabolism, neurodegeneration
MeSH terms
Alzheimer Disease, Apolipoproteins, Apolipoproteins E, Biology, Central Nervous System, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review